BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 22959556)

  • 1. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
    Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
    Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
    Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
    Nishio Y; Kimura H; Sawada N; Sugaru E; Horiguchi M; Ono M; Furuta Y; Sakai M; Masui Y; Otani M; Hashizuka T; Honda Y; Deguchi J; Nakagawa T; Nakahira H
    Bioorg Med Chem; 2011 Sep; 19(18):5490-9. PubMed ID: 21865048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group.
    Yoshida T; Akahoshi F; Sakashita H; Sonda S; Takeuchi M; Tanaka Y; Nabeno M; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Aug; 20(16):5033-41. PubMed ID: 22824762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
    J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].
    Goda M; Akahoshi F; Ishii S; Terata R; Hayashi Y
    Nihon Yakurigaku Zasshi; 2013 Sep; 142(3):134-43. PubMed ID: 24025495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.